Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian (JNJ-70033093) vs enoxaparin for VTE prevention after elective total knee replacement
jRCT2080224963Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of milvexian in venous thromboembolism (VTE) (8 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Total venous thromboembolism rate for pooled twice-daily milvexian regimens vs prespecified 30% target and Dose-response trend across milvexian twice-daily regimens. Started Nov 2019; status: completed.
02
Drugs
milvexian
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on jRCT2080224963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224963.